Presentation is loading. Please wait.

Presentation is loading. Please wait.

Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

Published byGuus Maes Modified over 5 years ago

Similar presentations

Presentation on theme: "Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting"— Presentation transcript:

1 Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting
Rituximab maintenance after induction with abbreviated FCR in previously untreated elderly ( 65 years) CLL patients : results of the randomized CLL 2007 SA trial from the French FILO Group Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

2 Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting
Introduction Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

3 Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting
Study design - CLL 2007 SA Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

4 Methodology and objectives - CLL 2007 SA
Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

5 Treatment regimen - CLL 2007 SA
Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

6 Main inclusion - randomization criteria - CLL 2007 SA
Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

7 Patient disposition - CLL 2007 SA
Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

8 Patient characteristics - CLL 2007 SA
Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

9 Patient characteristics - CLL 2007 SA
Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

10 Patient characteristics - CLL 2007 SA
Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

11 Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting
Safety profile - CLL 2007 SA Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

12 Hematologic toxicity - CLL 2007 SA
Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

13 Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting
Second cancers - CLL 2007 SA Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

14 Progression-free survival - CLL 2007 SA
Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

15 Subgroup analysis of progression-free survival - CLL 2007 SA
Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

16 Overall survival - CLL 2007 SA
Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

17 Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting
Conclusions - CLL 2007 SA Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

18 Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting
Acknowledgments Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

Download ppt "Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting"

Similar presentations

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
What is the Optimal Approach to CLL, BR vs. FCR/FR?

What is the Optimal Approach to CLL, BR vs. FCR/FR?
Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed.

Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed.
Goede V et al. Proc ASCO 2013;Abstract 7004.

Goede V et al. Proc ASCO 2013;Abstract 7004.
Does Chlorambucil Add to Obinutuzumab in the Treatment of the Unfit CLL Patient? NO Richard R. Furman, MD CLL Research Center.

Does Chlorambucil Add to Obinutuzumab in the Treatment of the Unfit CLL Patient? NO Richard R. Furman, MD CLL Research Center.
CORAL: COllaborative trial in Relapsed Aggressive Lymphoma R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed.

CORAL: COllaborative trial in Relapsed Aggressive Lymphoma R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed.
Presented By Patrick Wen at 2014 ASCO Annual Meeting

Presented By Patrick Wen at 2014 ASCO Annual Meeting
Presented By Raymond Huang at 2014 ASCO Annual Meeting

Presented By Raymond Huang at 2014 ASCO Annual Meeting
CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.

CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.
Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent.

Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS , ONO-4538) and ipilimumab (IPI) concurrent.
Prevention of Early Menopause Study (POEMS)-S0230 Phase III trial of LHRH analog during chemotherapy to reduce ovarian failure in early stage, hormone.

Prevention of Early Menopause Study (POEMS)-S0230 Phase III trial of LHRH analog during chemotherapy to reduce ovarian failure in early stage, hormone.
A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy Presented By Eudocia Lee at 2014.

A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy Presented By Eudocia Lee at 2014.
Eastern cooperative oncology group E1496: ECOG and CALGB Cyclophosphamide/Fludarabine (CF) with or without Maintenance Rituximab (MR) in Advanced Indolent.

Eastern cooperative oncology group E1496: ECOG and CALGB Cyclophosphamide/Fludarabine (CF) with or without Maintenance Rituximab (MR) in Advanced Indolent.
Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the.

Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the.
The Clinical Trials of HDC/ABMT in Women with Breast Cancer Prof Cindy Farquhar MD MPH University of Auckland, NZ.

The Clinical Trials of HDC/ABMT in Women with Breast Cancer Prof Cindy Farquhar MD MPH University of Auckland, NZ.
Pancreatic Cancer Ali Shamseddine MD Proessor of Medicine AUBMC

Pancreatic Cancer Ali Shamseddine MD Proessor of Medicine AUBMC
Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.

Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS , ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid.

A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid.
A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.

A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.
A Randomized Phase II Study Comparing Consolidation with a Single Dose of 90 Y Ibritumomab Tiuxetan (Zevalin ® ) (Z) vs Maintenance with Rituximab (R)

A Randomized Phase II Study Comparing Consolidation with a Single Dose of 90 Y Ibritumomab Tiuxetan (Zevalin ® ) (Z) vs Maintenance with Rituximab (R)

Similar presentations

Ads by Google